For people in recovery from opioid addiction, choosing the right medication is not just about stabilization. It is also about what happens when it is time to taper or stop. One of the most common comparisons today is between Suboxone and Sublocade, especially when it comes to withdrawal.
Both medications contain Buprenorphine, but how they are delivered changes the withdrawal experience significantly. At Brooks Healing Center, this is one of the most important conversations we have with patients planning long-term recovery.
The Core Difference: Daily vs Long-Acting Buprenorphine
The main distinction between these medications is how they enter and leave the body.
- Suboxone is taken daily as a film or tablet
- Sublocade is given as a monthly injection that slowly releases medication over time
Because of this, withdrawal from each looks very different.
Suboxone Withdrawal: What to Expect
With Suboxone, withdrawal depends heavily on how the medication is stopped.
Key Characteristics
- Withdrawal typically begins 24 to 72 hours after the last dose
- Symptoms often peak within 3 to 5 days
- Lingering symptoms can last 2 to 4 weeks or longer
Common Symptoms
- Anxiety and restlessness
- Muscle aches
- Insomnia
- Sweating
- Irritability
- Cravings
- Gastrointestinal distress
Because Suboxone is taken daily, stopping abruptly can lead to a noticeable drop in buprenorphine levels, which triggers withdrawal.
The Challenge
Even with tapering, many patients experience uncomfortable symptoms because each dose reduction creates a new adjustment period.
Sublocade Withdrawal: A Different Experience
Withdrawal from Sublocade tends to be delayed and more gradual.
This is because the medication forms a depot under the skin that releases buprenorphine steadily over weeks to months.
Key Differences
- No immediate “last dose” drop-off
- Medication levels decline slowly over time
- Withdrawal may be milder for some patients
- Onset is often delayed by weeks, not days
Table 1. Sublocade Withdrawal Timeline
| Timeframe | What’s Happening | Common Symptoms |
|---|---|---|
| Weeks 1–4 after last injection | Medication levels still relatively stable | Little to no withdrawal for many patients |
| Weeks 4–8 | Gradual decline begins | Mild fatigue, subtle mood changes |
| Weeks 8–12 | Noticeable decrease in buprenorphine levels | Mild anxiety, sleep disruption, low energy |
| Months 3–6+ | Continued slow taper from body stores | Intermittent symptoms, often less intense than Suboxone withdrawal |
| Beyond 6 months | Final elimination phase | Minimal to mild lingering symptoms in some cases |
Why Sublocade Withdrawal Can Feel Easier
The key factor is pharmacokinetics, or how the drug leaves the body.
With Suboxone:
- Daily dosing creates peaks and drops
- Stopping causes a relatively fast decline
With Sublocade:
- The body tapers itself gradually
- There is no abrupt change
This slow release can reduce the intensity of withdrawal symptoms for some patients.
Important Reality: Not Everyone Has an “Easy” Withdrawal
It is important to be clear and accurate.
Even with Sublocade:
- Withdrawal can still occur
- Some patients experience prolonged low-level symptoms
- Mental health factors still play a major role
- Individual metabolism and treatment history matter
There is no completely symptom-free option, only different withdrawal patterns.
Using Sublocade as a Taper Strategy
Many providers now use Sublocade as a structured way to taper off Suboxone.
Because it releases medication slowly, it allows the body to adjust gradually without the repeated daily dose reductions required with Suboxone. For some patients, this can reduce the severity of withdrawal compared to stopping sublingual formulations, especially when guided by a provider.
This approach is not instant, but it is often more controlled and predictable.
Sublocade Tapering (General Clinical Framework)
Because Sublocade is long-acting, tapering does not work like daily Suboxone reductions. Instead of step-down dosing every few days, the taper is typically achieved by spacing injections, reducing dose strength, or stopping after stabilization and allowing the medication to naturally decline.
Below is a realistic, clinically-aligned example of how a Sublocade taper may be structured. Actual plans vary by provider and patient history.
Table 2. Sample Sublocade Taper Schedule
| Phase | Timeframe | Typical Approach | What’s Happening in the Body | Patient Experience |
|---|---|---|---|---|
| Stabilization Phase | Months 1–2 | 300 mg monthly injections | Rapid receptor saturation and stabilization | Cravings controlled, minimal withdrawal |
| Maintenance Phase | Months 3–6+ | 100 mg monthly injections | Steady-state buprenorphine levels maintained | Emotional and physical stability improves |
| Early Taper Option A | Month 6+ | Continue 100 mg but extend interval (5–6 weeks) | Slight decline between doses | Usually minimal symptoms, mild fatigue possible |
| Early Taper Option B | Month 6+ | Final 100 mg injection then discontinue | Body begins slow natural taper | No immediate withdrawal due to depot release |
| Natural Taper Phase | Months 2–4 after last injection | No additional dosing | Gradual reduction of buprenorphine levels | Subtle mood shifts, mild sleep changes possible |
| Mid Taper Phase | Months 3–6 after last injection | Continued elimination | Receptor activity slowly decreases | Mild anxiety, low energy, intermittent symptoms |
| Late Taper Phase | Months 6+ after last injection | Final clearance phase | Very low residual levels | Minimal symptoms for many, occasional lingering effects |
Table 3. Suboxone vs. Sublocade Withdrawal Comparison
| Factor | Suboxone | Sublocade |
|---|---|---|
| Dosing | Daily | Monthly injection |
| Withdrawal Onset | 1–3 days | Weeks to months |
| Peak Symptoms | 3–5 days | Less defined, more gradual |
| Duration | Weeks | Months (but often milder) |
| Intensity | Moderate to severe (varies) | Often milder, but longer |
| Taper Control | Manual taper required | Built-in slow taper effect |
Which Option Is Better?
There is no universal answer.
Suboxone may be better for:
- Flexible dosing
- Short-term stabilization
- Patients early in treatment
Sublocade may be better for:
- Long-term stability
- Reducing daily medication burden
- Patients planning to taper off buprenorphine
- Those sensitive to withdrawal swings
The right choice depends on the individual, not just the medication.
The Bottom Line
Both Suboxone and Sublocade are effective treatments for opioid use disorder. The difference is not whether withdrawal happens, but how it happens. Suboxone withdrawal tends to be more immediate and defined. Sublocade withdrawal is slower, more gradual, and for some patients, easier to tolerate.
If you are thinking about tapering off buprenorphine, the approach matters just as much as the medication itself. At Brooks Healing Center, treatment plans are built around long-term recovery, including how to safely reduce and eventually stop medication when the time is right.
Frequently Asked Questions About Sublocade vs. Suboxone Withdrawal
Can Sublocade cause precipitated withdrawal?
Sublocade does not usually cause precipitated withdrawal when it is used correctly. The risk mainly comes from starting buprenorphine too early while full opioids are still active in the body. Because Buprenorphine binds strongly to opioid receptors, it can displace other opioids and trigger sudden withdrawal if proper induction steps are skipped. In practice, patients are stabilized first on a medication like Suboxone before transitioning, which significantly reduces this risk.
Which is best between Sublocade, Suboxone, and other medications?
There is no single medication that is universally best for everyone. Suboxone works well for people who need flexible daily dosing and early-stage stabilization, while Sublocade is often preferred for long-term stability because it provides consistent medication levels without daily dosing. Other options like Methadone or Naltrexone may be appropriate depending on tolerance level, treatment setting, and whether a person wants an agonist or blocker-based approach. The best choice is always the one that controls cravings, prevents relapse, and fits the person’s lifestyle and clinical needs.
Is Sublocade better than Suboxone?
Sublocade is not inherently better than Suboxone, but it can be a better fit for certain patients. Because Sublocade provides a steady release of buprenorphine over time, many people experience more consistent symptom control and fewer fluctuations. This can be especially helpful for individuals who struggle with daily adherence or who are planning to taper off buprenorphine in a more gradual way. Suboxone, on the other hand, offers more flexibility in dosing and is often used earlier in treatment.
Does Sublocade have a blocker like naloxone in it?
Sublocade does not contain naloxone. Unlike Suboxone, which includes Naloxone to discourage misuse, Sublocade relies on its delivery system. The medication forms a depot under the skin and releases slowly over time, which makes it difficult to misuse and removes the need for a blocker component.
Can you take Suboxone on Sublocade?
In some situations, a provider may prescribe Suboxone while a patient is on Sublocade, but this is not typical for long-term use. Because Sublocade already provides continuous buprenorphine levels, additional dosing is usually unnecessary. There are cases during transitions or when breakthrough symptoms occur where short-term use may be appropriate, but this should always be guided by a medical professional rather than self-managed.
Sources
- Hayes, V., Mills, L., Byron, G., Stubley, C., Black, E., Trevitt, B. T., Somogyi, A. A., Sahid, A., & Lintzeris, N. (2025). Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series. Drug and Alcohol Dependence Reports, 15, 100329. https://pubmed.ncbi.nlm.nih.gov/40276009/
- Ritvo, A. D., Calcaterra, S. L., & Ritvo, J. I. (2021). Using extended release buprenorphine injection to discontinue sublingual buprenorphine: A case series. Journal of Addiction Medicine, 15(3), 252–254. https://pubmed.ncbi.nlm.nih.gov/32925232/
- Jones, A. K., Ngaimisi, E., Gopalakrishnan, M., Young, M. A., & Laffont, C. M. (2021). Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: A combined analysis of Phase II and Phase III trials. Clinical Pharmacokinetics, 60(4), 527–540. https://pmc.ncbi.nlm.nih.gov/articles/PMC8016750/
- Rodriguez, C. P., Zhao, K., Grossman, E., & Heo, M. (2023). Case series: Voluntary discontinuation of sublingual buprenorphine treatment after extended-release buprenorphine. The American Journal on Addictions, 32(5), 503–506. https://pmc.ncbi.nlm.nih.gov/articles/PMC10121911/
- U.S. Food and Drug Administration. (2025). Sublocade prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209819s031lbl.pdf
- U.S. Food and Drug Administration. (2025). Suboxone sublingual film prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022410s057lbl.pdf
- Andorn, A. C., Haight, B. R., Shinde, S., Fudala, P. J., Zhao, Y., Heidbreder, C., & Jones, A. K. (2020). Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. Journal of Clinical Psychopharmacology, 40(3), 231–239. https://pmc.ncbi.nlm.nih.gov/articles/PMC7188268/
- Substance Abuse and Mental Health Services Administration. (2024). TIP 63: Medications for opioid use disorder. https://www.samhsa.gov/resource/ebp/tip-63-medications-opioid-use-disorder
